FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

ResMed Updates Labeling for Masks with Magnets

FDA says ResMed has issued updated instructions for its masks with magnets to inform users about potential magnetic interference when magnets are near...

latest-news-card-1
Human Drugs

Rare Disease Drug Development Guidance

FDA publishes a guidance to assist sponsors in conducting efficient and successful drug development programs to treat rare diseases.

latest-news-card-1
Human Drugs

Drug Development Master Protocol Guidance

FDA publishes a draft guidance making recommendations on the design and analysis of drug development trials conducted under a master protocol.

latest-news-card-1
Human Drugs

Updated Labeling for Promethazine HCl

FDA requires updated labeling for promethazine HCl injection to recommend administration through deep intramuscular rather than intravenous administra...

latest-news-card-1
Biologics

Cell/Gene Product Potency Assurance

FDA publishes a draft guidance on developing a science- and risk-based strategy to help assure the potency of a human cellular therapy or gene therapy...

latest-news-card-1
Human Drugs

CGMP Violations at Patco Cosmetics

FDA warns Indias Patco Cosmetics about CGMP violations in its manufacturing of finished over-the-counter drugs.

latest-news-card-1
Human Drugs

Dont Use Counterfeit Ozempic: FDA

FDA says it has seized thousands of units of counterfeit Ozempic that also contain counterfeit needles.

latest-news-card-1
Human Drugs

Califf Discusses More Clinical Research Options

FDA commissioner Robert Califf says a new final rule allowing some waivers of informed consent will enable minimal-risk research that would not otherw...

latest-news-card-1
Human Drugs

Topical Ophthalmic Quality Guidance

FDA publishes a draft guidance revising a recent draft on quality considerations for topical ophthalmic drugs.

latest-news-card-1
Human Drugs

CGMP Violations in Omeza Inspection

FDA warns Sarasota, FL-based Omeza about CGMP violations in its production of unapproved and misbranded over-the-counter drugs.